Shirley Rebecca, Fazekas Janka, McNally Martin, Ramsden Alex
Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford, OX3 7HE.
J Bone Jt Infect. 2018 Feb 5;3(1):15-19. doi: 10.7150/jbji.22186. eCollection 2018.
: This study aimed to define the costs of surgical management of chronic osteomyelitis where free tissue transfer was required in addition to debridement of bone, particularly the increased costs incurred by a return to theatre. We hypothesised that there would be a significantly greater cost when patients required re-exploration for vascular compromise. : We retrospectively analysed the costs of a consecutive series of sixty patient episodes treated at the Bone Infection Unit in Oxford from 2012 to 2015. Treatment involved excision of osteomyelitis with free tissue transfer for immediate soft tissue cover. We compared the costs of uncomplicated cases with those who returned to theatre and determined the profit / loss for the hospital from renumeration through the UK National Health Service Tariff Structure. : Hospital income according to UK HRG tariff was compared to the actual cost of treatment and these 60 cases were significantly underfunded overall (P < 0.005). In just 1 case, the cost to the hospital was completely covered by tariff. Six patients (10%) returned to theatre for urgent flap re-exploration with five flaps salvaged and one failed, requiring another free flap reconstruction (1.7%). These six patient episodes had a significantly higher mean cost compared to the uncomplicated cases. The average financial loss to the hospital for patients who did return to theatre was £19401 (range £8103 to £48380) and in those who did not was £9600 (range - £600 to £23717). The case requiring further free tissue transfer cost a total of £74158, £48380 more than the hospital was paid: the most extreme discrepancy. The overall loss for this group of 60 patients was £610 090. : Surgery for chronic osteomyelitis is multidisciplinary, complex and therefore expensive with a significant risk of complications. However, this study demonstrates that the hospital currently makes a financial loss on almost all patients but especially if flap complications occur. This study has implications for the long term viability of specialist units treating this important disease.
本研究旨在确定慢性骨髓炎手术治疗的成本,其中除了进行骨清创外还需要进行游离组织移植,特别是因再次手术而增加的成本。我们假设,当患者因血管并发症需要再次手术时,成本会显著更高。
我们回顾性分析了2012年至2015年在牛津骨感染科接受治疗的连续60例患者的成本。治疗包括切除骨髓炎并进行游离组织移植以立即覆盖软组织。我们将无并发症病例的成本与返回手术室的病例的成本进行了比较,并通过英国国家医疗服务体系收费结构确定了医院的利润/亏损情况。
根据英国HRG收费标准的医院收入与实际治疗成本进行了比较,这60例病例总体资金严重不足(P < 0.005)。仅1例患者的治疗成本完全由收费覆盖。6名患者(10%)返回手术室进行紧急皮瓣再次探查,5个皮瓣得以挽救,1个失败,需要再次进行游离皮瓣重建(1.7%)。与无并发症病例相比,这6例患者的平均成本显著更高。返回手术室的患者给医院造成的平均经济损失为19401英镑(范围为8103英镑至48380英镑),未返回手术室的患者为9600英镑(范围为 - 600英镑至23717英镑)。需要进一步进行游离组织移植的病例总成本为74158英镑,比医院获得的报酬多48380英镑:差异最为极端。这60名患者的总体损失为610090英镑。
慢性骨髓炎手术是多学科的、复杂的,因此成本高昂且并发症风险很大。然而,本研究表明,医院目前几乎在所有患者身上都出现了经济亏损,尤其是在发生皮瓣并发症的情况下。本研究对治疗这种重要疾病的专科单位的长期生存能力具有启示意义。